ResearchRSS2 days ago
Researchers found that a simple electrical test using surface electrodes on the skin can measure nerve signals in people with spinal muscular atrophy (SMA). These signals were much weaker in SMA patients compared to healthy people, which suggests this test could be a useful way to track how the disease changes over time.
WHY IT MATTERSIf validated, this non-invasive surface electrode test could provide a faster, easier, and cheaper way to monitor SMA progression in clinical trials and patient care compared to current muscle strength assessments.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for people with Spinal Muscular Atrophy (SMA) is currently closed and not accepting new applications. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them. You can check the program website to see when it reopens or find other financial help options.
WHY IT MATTERSIf you have SMA and struggle to afford your treatment, knowing this fund is temporarily closed helps you explore alternative financial assistance programs before your medication runs out.
Clinical trialCLINICALTRIALS4 days ago
Williams syndrome is a rare genetic condition that affects about 1 in every 8,000 to 12,000 people. It happens when a person is missing a small section of DNA on chromosome 7, which includes the gene that makes elastin (a protein that helps blood vessels stretch). This causes distinctive facial features and heart and blood vessel problems. Researchers are now recruiting 1,099 people with Williams syndrome or a related heart condition called supravalvular aortic stenosis to donate DNA and tissue samples to help scientists better understand these conditions.
WHY IT MATTERSThis actively recruiting biobank offers Williams syndrome and SVAS patients a direct way to contribute DNA and tissue samples to NHLBI-sponsored research that could accelerate understanding of the genetic causes and lead to new treatments.
ResearchBIORXIV5 days ago
Researchers studied blood samples from children with dengue virus infection to find early warning signs that could predict who will develop severe disease. By analyzing proteins in the blood, they identified markers related to inflammation and blood vessel damage that appear in children who get sicker. This discovery could help doctors quickly identify which children need more intensive care.
WHY IT MATTERSIf validated, these protein markers could enable doctors to predict dengue severity within hours of diagnosis in children, allowing earlier intervention before complications like hemorrhagic fever or shock develop.
ResearchCLINICALTRIALSApr 14
Researchers completed a small study with 14 children who have rare diseases and their parents to test whether a social robot could help families cope better. The robot was designed to provide support and improve relationships between parents and children while reducing stress and worry. The study looked at whether families found the robot helpful and acceptable to use in their daily lives.
WHY IT MATTERSThis completed trial demonstrates a novel approach to family-centered support for rare disease patients—social robots may offer accessible emotional and relational support when specialized mental health resources for rare disease families are limited.
Clinical trialCLINICALTRIALSApr 9
Researchers at Columbia University are looking for 106 children and young adults with Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy Type 3 (SMA Type 3) to join a study. The study will use special sensors and technology to track how people walk and move in their daily lives over a long period of time. The goal is to find new ways to measure how these diseases are progressing so doctors can better understand and treat them.
WHY IT MATTERSThis trial is now actively recruiting participants with DMD and SMA Type 3, offering a chance to contribute to developing better measurement tools that could help doctors track disease progression and evaluate future treatments more accurately.
Clinical trialCLINICALTRIALSApr 8
Researchers completed a small study testing whether a drug called Adalimumab (brand name Humira) could help people with Netherton syndrome, a rare skin condition that causes severe itching, rashes, and inflammation. Eleven patients received the drug for 3 months and were then followed for another 3 months to see if it was safe and if it improved their symptoms, including pain and itching.
WHY IT MATTERSThis completed trial provides evidence about whether Humira—a drug already used for other inflammatory conditions—could be repurposed to treat Netherton syndrome, which currently has very limited treatment options.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called ManNAc to treat primary focal segmental glomerulosclerosis (FSGS), a rare kidney disease that causes scarring and can lead to kidney failure. This is a Phase 2 trial, meaning the drug has already been tested for safety in a small group and now researchers want to see if it actually works to help patients. The trial is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers patients with primary FSGS access to an investigational treatment that may slow or stop kidney damage, with enrollment now open at sites participating in the National Human Genome Research Institute study.
Clinical trialUNITERAREApr 5
Researchers are testing a new tool called the Esophageal String Test to help diagnose eosinophilic esophagitis, a condition where too many white blood cells build up in the food pipe and cause trouble swallowing. The test uses a small string that you swallow to collect samples from your esophagus. This study is enrolling people in Mali and the United States who have difficulty swallowing.
WHY IT MATTERSThis trial offers a potentially simpler, non-invasive screening method for eosinophilic esophagitis that could reduce the need for traditional endoscopy procedures, particularly for underserved populations in Africa and the US.
Clinical trialUNITERAREApr 4
Researchers at Dartmouth-Hitchcock Medical Center are testing a therapy called TF-CBT (Trauma-Focused Cognitive Behavioral Therapy) to see if it works well for autistic young people. This is a pilot study, which means it's a small test to see if the approach is worth studying more carefully. The study is now accepting participants and is expected to start in April 2026.
WHY IT MATTERSThis trial addresses a significant gap in mental health treatment for autistic youth, as trauma-focused therapies are often adapted without testing whether they work safely and effectively for autistic individuals.
Clinical trialUNITERAREApr 3
Researchers at St. Jude Children's Research Hospital are testing a drug called entrectinib to treat very young children (under 3 years old) who have brain or spinal cord tumors caused by changes in specific genes called NTRK1, NTRK2, NTRK3, or ROS1. This is a Phase 2 trial, meaning they've already tested the drug in a small group and now want to see if it works well in more patients. The trial is now accepting new patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a targeted treatment option specifically designed for infants and toddlers with NTRK- or ROS1-fused CNS tumors, a group that has historically had very limited treatment options and poor outcomes.
Clinical trialUNITERAREApr 3
Researchers are testing a new experimental drug called EPI-326 in people with two types of cancer: non-small cell lung cancer and head and neck cancer, both caused by mutations in the EGFR gene. This is an early-stage study (Phase 1) to see if the drug is safe and how much patients can tolerate. The study is currently accepting new participants and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a novel EGFR-targeted therapy for patients with EGFR-mutant lung or head and neck cancers who may have limited treatment options or resistance to current therapies.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for paroxysmal nocturnal hemoglobinuria (PNH) — a rare blood disorder where red blood cells break down too quickly — is currently closed and stopped accepting new applications as of April 2, 2026. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. Patients who need financial help with their PNH medications should check the PAN Foundation website for updates on when the fund might reopen.
WHY IT MATTERSPatients with PNH who were relying on this $12,000 annual benefit to afford their medications now need to find alternative financial assistance programs immediately, as this major funding source is no longer available.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for spinal muscular atrophy (SMA) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have spinal muscular atrophy and need help paying for medications like Zolgensma or Spinraza, you'll need to explore other financial assistance programs since this major funding source is temporarily unavailable.
ResearchBIORXIVApr 2
Researchers developed a new artificial intelligence system called GEN-KnowRD to help doctors recognize rare diseases faster and more accurately. Currently, patients with rare diseases wait years for a correct diagnosis because doctors don't have good tools to identify these uncommon conditions. This new AI system is designed to work better than previous attempts by using a smarter approach that doesn't require as much expert knowledge to keep updated.
WHY IT MATTERSFaster rare disease diagnosis could reduce the average diagnostic odyssey from years to months, allowing patients to access treatment and clinical trials earlier when interventions are most effective.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.
WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
ResearchPUBMEDApr 1
Researchers reviewed 78 studies about early satiety (feeling full quickly after eating small amounts) in cancer patients. They found this symptom is common but often overlooked, and doctors don't have consistent ways to measure or describe it. The review shows there are big gaps in how we understand and treat this problem for cancer patients.
WHY IT MATTERSEarly satiety causes cancer patients to eat less and lose weight, which can weaken their ability to fight cancer and recover from treatment—but doctors rarely screen for or address this specific symptom.
ResearchCLINICALTRIALSMar 30
Researchers at Children's National completed a study testing a new support program for parents of children with rare diseases. The program, called Rare Group Problem Management Plus, brought parents together once a week for 5 weeks to help them manage stress, anxiety, and emotional challenges. The small study included 8 parents and focused on teaching practical coping skills in a group setting where everyone had similar experiences.
WHY IT MATTERSThis completed trial demonstrates that group-based support programs specifically designed for parents of children with rare conditions can address the significant mental health burden these families face, potentially offering a scalable model for other rare disease communities.
ResearchBIORXIVMar 30
Researchers developed a new computer tool called PhenoSS that helps doctors diagnose rare diseases more accurately by analyzing patient symptoms in a smarter way. Instead of just matching symptoms one-by-one, this tool understands how symptoms relate to each other and accounts for differences in how different doctors record patient information. This could help patients get diagnosed faster and more correctly.
WHY IT MATTERSIf this tool becomes available in clinical practice, patients with rare diseases could receive accurate diagnoses faster by having their symptom patterns analyzed more intelligently, potentially reducing the average diagnostic odyssey timeline.